UCBJY News and Press, UCB S.A. ADR From 11/05/21

UCB Showcases Key Rheumatology Data at ACR Convergence 2021 -- Eleven abstracts across UCB's rheumatology portfolio, including investigational bimekizumab and CIMZIA® (certolizumab pegol), underscore UCB's dedication to rheumatology -- Long-term three-year data from Pha...

Sharecare and UCB to present on future of decentralized clinical research at 2021 CNS Summit Spotlight session highlighting Sharecare's efforts to advance real-world relevance, equity, and data integrity in clinical research scheduled for Monday, Nov. 8 at 2 p.m. EST PR News...

UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab - ImageBiopsy Lab will further develop and launch an AI-based fracture identification tool based on UCB-developed BoneBot AI technology which detects the presence of "silent" or asym...

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab - The U.S. FDA has informed UCB via letter that the Agency was unable to complete review of the BLA for bimekizumab by the PDUFA date and is deferring action on the application - The Agency cite...

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress -- Interim results from the BE BRIGHT open-label extension study showed clinical responses observed in bimekizumab-treated patients...

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older - Tablets, oral solution, and IV (or intravenous) dosage forms of BRIVIACT® (brivaracetam) CV now FDA-approved as both monotherap...

UCB SA (UCBJF) Q2 2021 Results Conference Call July 29, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl - E...

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis - Today, two manuscripts published back to back detail the full results from the BE RADIANT and BE SURE studies, comparing the efficacy and safety ...

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 PR Newswire BRUSSELS , April 23, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 12 abstracts on bimekizumab, an investigational IL-17A and IL-17F inhibitor, in the...

UCB SA (UCBJF) Q4 2020 Results Conference Call February 25, 2021 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO Emmanuel Caeymaex - EVP, Head, Immunology Patient Value Unit Iris Löw-Friedrich - Chief Medical Officer Sandrine Dufour - CFO Charl Van Zyl...